Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab

INTRODUCTION: Chemoradiotherapy with taxanes is well-recognized as a first-line therapy for cutaneous angiosarcoma (CAS), but second-line therapy for CAS is still controversial. CASE PRESENTATION: In this report, we described a 75-year-old Japanese case of recurrent, tumor mutation burden-high CAS o...

Descripción completa

Detalles Bibliográficos
Autores principales: Amagai, Ryo, Fujimura, Taku, Kambayashi, Yumi, Ohuchi, Kentaro, Yamazaki, Emi, Hashimoto, Akira, Asano, Yoshihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684255/
https://www.ncbi.nlm.nih.gov/pubmed/38033417
http://dx.doi.org/10.1159/000534657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684255/
https://www.ncbi.nlm.nih.gov/pubmed/38033417
http://dx.doi.org/10.1159/000534657

Ejemplares similares